Revenue: As of FY2025, the actual value is USD 634.21 M, beating the estimate of USD 634 M.EPS: As of FY2025, the actual value is USD -0.09.EBIT: As of FY2025, the actual value is USD 75.63 M.<h4>Segment Revenue</h4><ul><li>Total Net Product Sales: Amicus Therapeutics, Inc. (爱美医疗) reported total net product sales of $634,210 thousand for the year ended December 31, 2025, an increase from $528,295 thousand in the prior year. This represents a $105,915 thousand increase, primarily driven by the growth of Galafold® and Pombiliti® + Opfolda®, and a $13,500 thousand favorable foreign currency exchange impact .</li><li>Galafold® Sales: Total Galafold® sales were $521,702 thousand in 2025, up from $458,054 thousand in 2024 . U.S. sales for Galafold® were $215,761 thousand in 2025, compared to $176,024 thousand in 2024, while Ex-U.S. sales reached $305,941 thousand in 2025, up from $282,030 thousand in 2024 .</li><li>Pombiliti® + Opfolda® Sales: Total Pombiliti® + Opfolda® sales significantly increased to $112,508 thousand in 2025 from $70,241 thousand in 2024 . U.S. sales for Pombiliti® + Opfolda® were $48,265 thousand in 2025, compared to $30,123 thousand in 2024, and Ex-U.S. sales were $64,243 thousand in 2025, up from $40,118 thousand in 2024 .</li></ul><h4>Operational Metrics</h4><ul><li>Cost of Goods Sold (COGS): COGS increased to $72,929 thousand in 2025 from $52,943 thousand in 2024, primarily due to higher net product sales .</li><li>Gross Profit: Gross profit for 2025 was $561,281 thousand, an increase from $475,352 thousand in 2024 .</li><li>Research and Development (R&amp;D) Expense: R&amp;D expenses rose by $26,481 thousand to $135,843 thousand in 2025 from $109,362 thousand in 2024, mainly due to a $30,000 thousand upfront license payment for DMX-200 .</li><li>Selling, General, and Administrative (SG&amp;A) Expense: SG&amp;A expenses increased by $60,108 thousand to $383,487 thousand in 2025 from $323,379 thousand in 2024, attributed to higher personnel costs and legal/professional fees related to intellectual property litigation and the BioMarin Merger Agreement .</li><li>Net Loss Attributable to Common Stockholders: Amicus Therapeutics, Inc. (爱美医疗) reported a net loss of -$27,110 thousand in 2025, an improvement from a net loss of -$56,106 thousand in 2024 .</li><li>Other (Expense) Income: The company recorded other expense of -$10,244 thousand in 2025, compared to other income of -$9,441 thousand in 2024, with the variance largely due to foreign exchange rate movements .</li></ul><h4>Cash Flow</h4><ul><li>Net Cash Provided by (Used in) Operating Activities: Net cash provided by operating activities was $33,145 thousand in 2025, a significant improvement from net cash used in operating activities of -$33,891 thousand in 2024 . This 2025 figure reflects a net loss of -$27,110 thousand, adjusted for non-cash expenses of $99,900 thousand and a net increase in operating assets and liabilities of $39,600 thousand .</li><li>Net Cash Used in Investing Activities: Net cash used in investing activities was -$46,432 thousand in 2025, primarily due to $94,405 thousand for marketable securities purchases and $3,296 thousand for capital expenditures, partially offset by $51,269 thousand from the sale and redemption of marketable securities .</li><li>Net Cash Provided by Financing Activities: Net cash provided by financing activities was $610 thousand in 2025, mainly from $19,205 thousand in proceeds from stock option exercises, partially offset by $18,323 thousand for employee withholding taxes related to restricted stock unit vesting .</li></ul><h4>Unique Metrics</h4><ul><li>Total Cash, Cash Equivalents, and Marketable Securities: As of December 31, 2025, Amicus Therapeutics, Inc. (爱美医疗) held $293,500 thousand in cash, cash equivalents, and marketable securities .</li><li>Inventories: Inventories, net, increased to $228,819 thousand as of December 31, 2025, from $118,782 thousand in 2024, driven by an increase in raw materials, work-in-process, and finished goods to support continued commercial growth .</li><li>Debt: The Senior Secured Term Loan due 2029 had a principal of $400,000 thousand as of December 31, 2025, with an effective interest rate of 11.1% . The company’s total contractual purchase and manufacturing obligations with third-party manufacturers amounted to $218,800 thousand as of December 31, 2025 .</li><li>Operating Lease Liabilities: Total operating lease liabilities were $49,703 thousand as of December 31, 2025, with a weighted-average remaining lease term of 7.7 years and a weighted-average discount rate of 9.7% .</li></ul><h4>Outlook / Guidance</h4>Amicus Therapeutics, Inc. (爱美医疗) expects continued significant costs for R&amp;D, clinical trials, and commercialization in the foreseeable future . Excluding the impact of the pending merger with BioMarin, the company believes its current cash position and expected revenues are sufficient to fund operations and research programs for at least the next 12 months . However, potential business development, pipeline expansion, and manufacturing investments could affect long-term capital requirements .

Amicus Therap | 10-K: FY2025 Revenue Beats Estimate at USD 634.21 M